Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsor: Novartis Pharmaceuticals
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified September 2010
Condition: Cerebral Aneursym
Interventions: Device: Micro Vention Hydrogel coil; Device: Non-hydrogel coils
Sponsors: University of Virginia; MicroVention Terumo
Recruiting - verified September 2010
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsor: Oxford BioMedica
Recruiting - verified September 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: placebo; Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: insulin aspart
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type II
Intervention: Drug: Insulin LISPRO
Sponsor: Halozyme Therapeutics
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Condition: HCV Infection
Interventions: Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo; Drug: GS-5885; Drug: Placebo
Sponsor: Gilead Sciences
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Insulin LISPRO
Sponsor: Halozyme Therapeutics
Recruiting - verified September 2010
Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Intracranial Hemorrhages
Interventions: Drug: Vitamin E; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Not yet recruiting - verified July 2010
Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsor: Innovative Medical
Not yet recruiting - verified September 2010
Conditions: Solid Tumors; Pancreatic Cancer; Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Myopia
Interventions: Device: galyfilcon A prototype; Device: enfilcon A
Sponsor: Vistakon
Recruiting - verified August 2010
Condition: Hemorrhage
Interventions: Biological: secondary hemostatic treatment; Device: Surgicel® Original
Sponsor: Nycomed
Not yet recruiting - verified August 2010
Conditions: Hyperphosphatemia; High Phosphorus; Dialysis; Kidney Failure
Intervention: Drug: ferric citrate, calcium acetate, sevelamer carbonate, placebo
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified September 2010
Condition: CLL
Intervention: Drug: Ofatumumab/HDMP
Sponsors: Chronic Lymphocytic Leukemia Research Consortium; GlaxoSmithKline
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Device: rTMS; Device: Sham Device
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified August 2010
Condition: Menorrhagia
Interventions: Drug: Lysteda; Drug: Lysteda
Sponsor: Ferring Pharmaceuticals
Recruiting - verified August 2010
Condition: Metabolic Syndrome
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Meganatural Gold®
Sponsor: University of California, Davis
Recruiting - verified August 2010
Conditions: Facial Rhytides; Crow's Feet Lines; Glabellar Lines
Interventions: Other: botulinum toxin type A and Normal Saline (placebo); Biological: botulinum toxin type A; Drug: Normal Saline
Sponsor: Allergan
Not yet recruiting - verified August 2010
Conditions: Lateral Canthus Rhytides; Crow's Feet Lines
Interventions: Biological: botulinum toxin type A; Drug: Normal Saline
Sponsor: Allergan
Not yet recruiting - verified August 2010
Condition: Osteoarthritis, Knee
Interventions: Other: Full Kinetic Chain Manipulative Therapy; Other: Full Kinetic Chain Rehabilitation; Other: Full Kinetic Chain Manipulative Therapy with Rehabilitation
Sponsors: Cleveland Chiropractic College; Durban University of Technology South Africa; Murdoch University
Not yet recruiting - verified August 2010
Conditions: Wet Macular Degeneration; Macular Degeneration; Pigment Epithelium of Eye; Retinal Detachment
Interventions: Drug: ranibizumab; Drug: ranibizumab
Sponsors: Pacific Eye Associates; Genentech
Recruiting - verified August 2010
Condition: Hepatitis C Virus
Interventions: Drug: PSI-7977 and SOC (PEG-IFN and RBV); Drug: PSI-7977
Sponsor: Pharmasset
Recruiting - verified August 2010
Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); NIH Office of Rare Diseases Research
Recruiting - verified August 2010
Conditions: Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin
Interventions: Procedure: 12Gy total skin electron beam therapy; Drug: Vorinostat
Sponsor: Stanford University
Not yet recruiting - verified August 2010
Condition: Heart Failure
Interventions: Drug: TRV120027; Drug: Placebo
Sponsor: Trevena Inc.
Not yet recruiting - verified August 2010
Conditions: Lymphoblastic Leukemia, Acute; Lymphoblastic Leukemia, Acute, Childhood; Leukemia, Lymphoblastic, Acute, T Cell; Leukemia, Lymphoblastic, Acute
Interventions: Drug: EZN-3042; Drug: Cytarabine; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Enzon Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: FBS0701; iron chelation
Sponsor: FerroKin BioSciences, Inc.
Recruiting - verified August 2010
Condition: Heart Transplant
Intervention: Drug: Pioglitazone
Sponsor: Stanford University
Recruiting - verified August 2010
Condition: Diabetes Mellitus
Intervention:
Sponsor: DexCom, Inc.
Recruiting - verified August 2010
Condition: Thalassemia
Intervention: Drug: Deferasirox
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Erythematous (Type One) Rosacea
Interventions: Drug: V-101; Other: vehicle
Sponsors: Vicept Therapeutics, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified August 2010
Conditions: HIV Infection; Gastrointestinal Symptoms
Interventions: Dietary Supplement: GanedenBC30, GBI-30, PTA-6086; Drug: Placebo
Sponsors: AIDS Healthcare Foundation; Ganeden Biotech, Inc.
Recruiting - verified August 2010
Conditions: Hepatitis C; Chronic
Interventions: Drug: DEB025 600 mg QD + SOC; Drug: DEB025 800 mg QD; Drug: placebo + SOC
Sponsor: Novartis
Recruiting - verified August 2010
Condition: Dementia
Intervention: Behavioral: Dementia Care Management
Sponsors: VA Greater Los Angeles Healthcare System; University of California, Los Angeles
Recruiting - verified August 2010
Condition: Sensorineural Hearing Loss
Intervention: Behavioral: Sound stimulation
Sponsor: Earlogic Korea, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network; Juvenile Diabetes Research Foundation
Not yet recruiting - verified August 2010
Conditions: Hypertension; Hypotension
Intervention:
Sponsor: Sotera Wireless, Inc.
Not yet recruiting - verified August 2010
Condition: Contraception
Interventions: Drug: Contraception; Drug: Contraception
Sponsor: Agile Therapeutics
Recruiting - verified August 2010
Condition: Normal Healthy Subjects
Interventions: Other: Hypothenar muscle activation--maximum, voluntary, isometric; Other: Thenar muscle activation--maximum, voluntary, isometric; Other: EDB muscle activation--maximum, voluntary, isometric
Sponsor: Loma Linda University
Not yet recruiting - verified August 2010
Condition: Hyperparathyroidism, Secondary
Interventions: Drug: Cinacalcet; Drug: Traditional Vitamin D Therapy
Sponsor: Amgen
Not yet recruiting - verified September 2010
Conditions: Lung Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer
Intervention: Procedure: Exhaled Breath Sampling
Sponsor: Stanford University
Recruiting - verified August 2010
Conditions: Cancer; Inflammation
Intervention:
Sponsor: University of California, Los Angeles
Recruiting - verified August 2010
Conditions: Autoimmune Diseases; Cancer
Intervention:
Sponsor: University of California, Los Angeles
Recruiting - verified August 2010
Condition: Cystic Fibrosis
Interventions: Drug: MP-376 (Levofloxacin solution for Inhalation); Drug: Placebo
Sponsor: Mpex Pharmaceuticals
Not yet recruiting - verified August 2010
Condition: Laminectomy
Intervention: Drug: Esmolol
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified March 2010
Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: LuAA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Colorectal Cancer
Intervention: Procedure: Early urinary catheter removal
Sponsor: Stanford University
Recruiting - verified August 2010
Condition: Kidney Transplantation
Intervention: Biological: Rituxan
Sponsors: Cedars-Sinai Medical Center; Genentech
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Conditions: Contraception; Female Contraception
Intervention: Drug: DR-102
Sponsor: Teva Women's Health
Recruiting - verified September 2010
Condition: Smoking Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo
Sponsors: Nabi Biopharmaceuticals; GlaxoSmithKline
Recruiting - verified August 2010
Condition: Subjective Tinnitus
Interventions: Device: Conventional sound generator (SG); Device: Placebo sound generator (placebo SG); Behavioral: Standard of Care (SC); Behavioral: Directive Counseling (DC); Behavioral: Directive Counseling (DC)
Sponsors: Johns Hopkins Bloomberg School of Public Health; National Institute on Deafness and Other Communication Disorders (NIDCD); University of Alabama, Tuscaloosa; David Grant U.S. Air Force Medical Center; Wilford Hall Medical Center; United States Naval Medical Center, San Diego; United States Naval Medical Center, Portsmouth; National Naval Medical Center; Naval Hospital Camp Pendleton
Not yet recruiting - verified August 2010
Condition: Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Interventions: Behavioral: Cognitive-Behavioral Therapy; Behavioral: Wait-list
Sponsors: University of South Florida; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, Los Angeles; University of Miami
Recruiting - verified August 2010
Condition: Intrauterine Growth Retardation
Interventions: Procedure: selective laser photocoagulation of communicating vessels; Procedure: Expected Management
Sponsor: University of South Florida
Recruiting - verified February 2008
Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Blood draw
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Condition: Birth Control
Interventions: Device: WC then FC2; Device: FC2 then WC
Sponsors: CONRAD; United States Agency for International Development (USAID); Program for Appropriate Technology in Health
Recruiting - verified August 2010
Condition: Respiration
Intervention: Device: Non-Contact Respiratory Rate Monitor
Sponsor: Kai Medical, Inc.
Recruiting - verified August 2010
Condition: Myopia
Interventions: Device: 1-Day ACUVUE® DEFINE™ with LACREON™ for light eye lenses (ZBC); Device: 1-Day ACUVUE® DEFINE™ with LACREON™ for light eye lenses (PBC); Device: 1-Day ACUVUE® Moist
Sponsor: Vistakon
Recruiting - verified August 2010
Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting - verified August 2010
Conditions: Orthostatic Hypotension; Parkinson's Disease
Intervention: Drug: Droxidopa
Sponsor: Chelsea Therapeutics
Recruiting - verified August 2010
Condition: Irritable Bowel Syndrome With Diarrhea
Interventions: Drug: Placebo; Drug: Mesalamine Granules 750 mg; Drug: Mesalamine Granules 1500 mg
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Condition: Rosacea
Interventions: Drug: CD07805/47 Gel; Drug: Vehicle Gel
Sponsor: Galderma
Recruiting - verified August 2010
Condition: Solid Tumor Cancers
Interventions: Drug: veliparib; Drug: Temozolomide
Sponsor: Abbott
Recruiting - verified August 2010
Condition: Food Addiction
Intervention: Drug: Naltrexone
Sponsor: University of California, San Francisco
Recruiting - verified July 2010
Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2010
Conditions: Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma
Interventions: Drug: flucytosine; Other: polymerase chain reaction; Other: immunohistochemistry staining method; Biological: gene therapy; Other: pharmacological study; Other: 3-Tesla magnetic resonance imaging; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Biological: E. coli CD-expressing genetically modified neural stem cells
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Conditions: Head and Neck Cancer; Liver Cancer; Breast Cancer; Gastric Cancer
Interventions: Drug: CUDC-101; Drug: CUDC-101
Sponsor: Curis, Inc.
Recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: 2.5 mcg tiotropium Respimat®; Drug: 5 mcg tiotropium Respimat®; Drug: 50 mcg salmeterol HFA MDI; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Not yet recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified August 2010
Condition: Stress Urinary Incontinence
Intervention: Device: Coloplast Virtue® Male Sling
Sponsor: Coloplast A/S
Recruiting - verified September 2010
Conditions: Chlamydia; Gonorrhea
Intervention:
Sponsor: Siemens Healthcare Diagnostics Inc
Recruiting - verified August 2010
Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsor: ZIOPHARM
Recruiting - verified August 2010
Condition: Advanced Solid Tumors
Intervention: Drug: ARQ 197 as monotherapy or in combination with other drug(s)
Sponsor: ArQule
Available - verified September 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: FOLFIRI regimen; Drug: FOLFOX regimen; Drug: capecitabine; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery
Sponsors: Walter Reed Army Medical Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Sickle Cell Anemia
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: General Anesthesia
Interventions: Drug: Propofol anesthesia; Drug: Sevoflurane anesthesia
Sponsor: University of California, San Francisco
Recruiting - verified August 2010
Condition: Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate 20mg/1.0ml; Drug: Glatiramer Acetate 20mg/0.5ml
Sponsor: Teva Neuroscience, Inc.
Recruiting - verified August 2010
Condition: Plaque Psoriasis
Interventions: Drug: Halobetasol Proprionate Lotion 0.05%; Drug: Halobetasol Proprionate Cream 0.05%
Sponsor: Therapeutics, Inc.
Recruiting - verified July 2010
Condition: Primary Immune Deficiency
Intervention: Biological: Subcutaneous IgG (SCIG)
Sponsor: CSL Behring
Recruiting - verified August 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peginterferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; ImClone LLC
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin aspart; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin detemir
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Dapagliflozin
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified July 2010
Condition: Hepatitis C, Chronic
Intervention:
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: Vilanterol; Drug: Salmeterol Inhalation Powder; Drug: Placebo Inhalation Powder NDPI; Drug: Placebo Inhalation Powder Diskus
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Furoate Inhalation Powder; Drug: Placebo Inhaltion Powder
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified August 2010
Condition: Depressive Disorder, Major
Interventions: Drug: Lu AA21004; Drug: Lu AA21004; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Not yet recruiting - verified September 2010
Condition: HIV Infection
Intervention: Drug: Raltegravir
Sponsors: Southern California Institute for Research and Education; Merck
Not yet recruiting - verified August 2010
Conditions: Complicated Grief; Bereavement
Interventions: Drug: Citalopram; Behavioral: Complicated Grief Treatment; Other: Placebo
Sponsors: Columbia University; National Institute of Mental Health (NIMH); American Foundation for Suicide Prevention
Recruiting - verified August 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: A-623; Drug: A-623; Drug: A-623; Other: Placebo Comparator
Sponsor: Anthera Pharmaceuticals
Recruiting - verified July 2010
Condition: Hemophilia A
Interventions: Drug: BAY94-9027; Drug: BAY94-9027
Sponsor: Bayer
Not yet recruiting - verified August 2010
Conditions: Leukemia; Leukemia Acute Lymphoid Leukemia (ALL)
Intervention: Drug: Velcade
Sponsors: Stanford University; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Intervention:
Sponsor: Medtronic Diabetes
Recruiting - verified August 2010
Condition: Cardiovascular Disease
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2010
Condition: Erectile Dysfunction
Interventions: Drug: LY2452473; Drug: tadalafil; Drug: placebo (tadalafil); Drug: placebo (LY2452473)
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Condition: Basal Cell Carcinoma
Intervention: Drug: GDC-0449
Sponsor: Genentech
Available - verified August 2010
Condition: Healthy
Interventions: Drug: PF-03463275; Drug: PF-03463275; Drug: PF-03463275; Drug: Placebo; Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified September 2010
Condition: Non-squamous Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel / Carboplatin; Drug: bavituximab
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified July 2010
Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsor: Amgen
Recruiting - verified August 2010
Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: CDX-011; Drug: "Investigator's Choice" chemotherapy
Sponsor: Celldex Therapeutics
Recruiting - verified August 2010
Condition: Healthy Volunteer
Interventions: Drug: RO5024048; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 and Exemestane; Drug: Placebo and Exemestane
Sponsor: Merrimack Pharmaceuticals
Recruiting - verified August 2010
Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Breast Cancer
Intervention: Device: Intraoperative Radiotherapy
Sponsor: Hoag Memorial Hospital Presbyterian
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified August 2010
Condition: Diabetes
Intervention: Procedure: Insulin, glucose and staple isotopes
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin; Lymphomas: Non-Hodgkin Peripheral T-Cell
Intervention: Drug: Nilotinib
Sponsors: Stanford University; Novartis
Recruiting - verified August 2010
Conditions: Ureteral Calculi; Kidney Stones; Urolithiasis
Interventions: Drug: silodosin; Drug: placebo
Sponsor: Watson Pharmaceuticals
Recruiting - verified August 2010
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine); Drug: TH-302; Drug: TH-302
Sponsors: Threshold Pharmaceuticals; PRA International
Recruiting - verified August 2010
Condition: Infertility
Interventions: Biological: SCH 900962 / Corifollitropin alfa / Org 36286; Biological: RecFSH / follitropin beta
Sponsor: Schering-Plough
Recruiting - verified August 2010
Condition: Infertility
Interventions: Biological: SCH 900962 / Corifollitropin alfa / Org 36286; Biological: RecFSH / follitropin beta
Sponsor: Schering-Plough
Recruiting - verified August 2010
Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsor: Healthpoint
Recruiting - verified August 2010
Condition: Intraocular Melanoma
Interventions: Drug: MEK inhibitor AZD6244; Drug: temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: Lurasidone HCl
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified August 2010
Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: Lurasidone HCl
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified September 2010
Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsor: Eisai Inc.
Recruiting - verified July 2010
Condition: Multiple Sclerosis
Interventions: Drug: ELND002; Drug: Placebo
Sponsor: Elan Pharmaceuticals
Recruiting - verified September 2010
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Parkinson Disease
Intervention:
Sponsors: Michael J. Fox Foundation for Parkinson's Research; Institute for Neurodegenerative Disorders
Recruiting - verified August 2010
Conditions: HIV-1 Infection; Neuropathic Pain
Intervention: Drug: pregabalin (Lyrica)
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Acne
Interventions: Drug: adapalene and benzoyl peroxide; Drug: Topical Gel Vehicle
Sponsor: Galderma
Recruiting - verified August 2010
Condition: Acute Gout
Interventions: Drug: ACZ885 (Canakinumab); Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat; Drug: Bevacizumab
Sponsor: Geron Corporation
Recruiting - verified August 2010
Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Sitagliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib; Biological: Trastuzumab; Drug: Docetaxel; Drug: Paclitaxel; Drug: Vinorelbine
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Non-Small-Cell Lung Cancer
Intervention: Drug: Docetaxel plus bavituximab or placebo
Sponsor: Peregrine Pharmaceuticals
Recruiting - verified August 2010
Condition: Chronic Hepatitis C Virus Genotype 1
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: Placebo; Drug: Peginterferon Alpha-2a; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Condition: Hepatocellular Carcinoma
Interventions: Drug: Placebo; Biological: Ramucirumab DP
Sponsor: ImClone LLC
Recruiting - verified August 2010
Conditions: Benign Prostatic Hyperplasia; Enlarged Prostate
Interventions: Drug: Tadalafil; Drug: Placebo; Drug: Finasteride
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CEP-33457; Drug: Placebo
Sponsor: Cephalon
Recruiting - verified August 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified August 2010
Conditions: Melanoma; BRAF Mutant Metastatic Melanoma
Intervention: Drug: GSK2118436
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Drug: AZD2066; Drug: Placebo; Drug: Duloxetine
Sponsor: AstraZeneca
Recruiting - verified August 2010
Condition: Intermittent Claudication
Interventions: Drug: Placebo; Drug: 375 mg CK-2017357; Drug: 750 mg CK-2017357
Sponsor: Cytokinetics
Recruiting - verified August 2010
Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Irritable Bowel Syndrome
Intervention: Drug: JNJ-27018966
Sponsor: Furiex Pharmaceuticals, Inc
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Olanzapine; Drug: Aripiprazole; Drug: Risperidone; Drug: Quetiapine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders
Interventions: Drug: PF-04991532; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Coronary Artery Disease
Interventions: Other: Stenting plus OMT; Other: Standard of care
Sponsor: St. Jude Medical
Recruiting - verified August 2010
Conditions: HER2-negative Breast Cancer; Metastatic Disease
Interventions: Drug: Zoledronic acid; Drug: Zoledronic acid; Drug: Zoledronic acid
Sponsor: Novartis
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsor: Eli Lilly and Company
Not yet recruiting - verified August 2010
Condition: Hypertension
Interventions: Drug: Placebo; Drug: Comparator: Amlodipine; Drug: Comparator: ISMN ER
Sponsor: Merck
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: LY2189265; Drug: Placebo (oral); Drug: Placebo (subcutaneous)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: peg-interferon alfa-2a; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Condition: Ulcerative Colitis
Intervention: Drug: MMX mesalamine/ mesalazine
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Otelixizumab; Biological: Placebo
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation; GlaxoSmithKline
Recruiting - verified May 2010
Condition: Nonarteritic Anterior Ischemic Optic Neuropathy
Intervention:
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Acute Myeloid Leukemia
Interventions: Drug: MDX-1338/BMS-936564 (Anti-CXCR4); Drug: MDX-1338/BMS-936564 (Anti-CXCR4)
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified July 2010
Condition: Metastatic Breast Cancer
Intervention: Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Available - verified August 2010
Condition: Osteoporosis
Interventions: Drug: odanacatib; Drug: Comparator: Placebo; Dietary Supplement: Comparator: Vitamin D3; Dietary Supplement: Comparator: Calcium carbonate
Sponsor: Merck
Recruiting - verified August 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium 2.5 mcg; Drug: tiotropium 5 mcg; Drug: Tiotropium 18 mcg; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Pelvic Organ Prolapse
Interventions: Procedure: Robotic Assisted Laparoscopic ASC; Procedure: Laparoscopic Abdominal Sacrocolpopexy
Sponsors: Loyola University; National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Recruiting - verified August 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Once-daily QVA149; Drug: once-daily NVA237; Drug: once-daily tiotropium
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Conditions: Sickle Cell Disease; Vaso-occlusive Crisis; Pain Crisis
Interventions: Drug: GMI-1070; Drug: Placebo
Sponsor: GlycoMimetics Incorporated
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: olanzapine; Drug: paliperidone; Drug: quetiapine; Drug: paliperidone palmitate; Drug: haloperidole; Drug: aripiprazole; Drug: risperidone; Drug: perphenazine
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified August 2010
Condition: Pelvic Pain Associated With Refractory Endometriosis
Interventions: Drug: BGS649; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified May 2010
Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
Sponsor: University of California, San Francisco
Recruiting - verified August 2010
Condition: Chronic Pain
Intervention: Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: trastuzumab-DM1; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified August 2010
Condition: Chlamydia Trachomatis
Interventions: Drug: doxycyline hyclate tablet; Drug: Vibramycin (doxycyline hyclate) capsule
Sponsor: Warner Chilcott
Recruiting - verified August 2010
Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Collaborative Study Group (CSG)
Recruiting - verified August 2010
Condition: Phenylketonuria
Interventions: Drug: Sapropterin dihydrochloride; Drug: Placebo
Sponsor: BioMarin Pharmaceutical
Recruiting - verified August 2010
Conditions: Orthopedic; Surgery; Elderly
Intervention: Drug: Lidocaine
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified March 2010
Condition: Progressive Supranuclear Palsy
Interventions: Drug: Davunetide; Drug: Placebo
Sponsor: Allon Therapeutics
Not yet recruiting - verified August 2010
Condition: Carpal Tunnel Syndrome
Intervention:
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified February 2010
Conditions: Lung Neoplasms; Carcinoma; Cancer of the Lung; Non-Small-Cell Lung Carcinoma
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: Vinorelbine
Sponsors: Bristol-Myers Squibb; Eli Lilly and Company
Recruiting - verified July 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Not yet recruiting - verified August 2010
Condition: Pancreatic Cancer
Interventions: Drug: Pertuzumab; Drug: Erlotinib
Sponsors: Stanford University; Genentech
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Other: Insulin Lispro 2 day reservoir in-use; Other: Insulin Lispro 6 Day reservoir in-use; Other: Insulin aspart 6 day reservoir in-use
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Dyslipidemia
Interventions: Drug: LY2484595; Drug: Atorvastatin; Drug: Simvastatin; Drug: Rosuvastatin; Drug: Placebo for LY2484595; Drug: Placebo for Statins
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Interventions: Other: Saline; Drug: Docetaxel; Drug: LY2181308
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Hemophilia A With Inhibitors
Interventions: Drug: recombinant activated factor VII; Drug: recombinant activated factor VII
Sponsor: Fondazione Ospedale Maggiore Policlinico Milano
Not yet recruiting - verified August 2010
Conditions: Breast Cancer; Melanoma
Intervention: Drug: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
Condition: SLE
Interventions: Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570; Drug: MEDI-570
Sponsors: MedImmune LLC; AstraZeneca
Recruiting - verified August 2010
Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine Dimesylate; Drug: Atomoxetine Hydrochloride
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Condition: Psoriasis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Sponsor: Cephalon
Recruiting - verified August 2010
Condition: Sexual Dysfunctions, Psychological
Intervention: Drug: flibanserin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsor: Andromeda Biotech Ltd.
Recruiting - verified August 2010
Condition: Type 2 Diabetes
Interventions: Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: BMS-820132; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Osteoarthritis
Interventions: Drug: PH-797804; Drug: Placebo; Drug: Placebo; Drug: PH-797804; Drug: Naproxen; Drug: Naproxen + PH-797804; Drug: Naproxen + PH-797804; Drug: Naproxen
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: eribulin mesylate + erlotinib; Drug: eribulin mesylate + erlotinib
Sponsor: Eisai Inc.
Recruiting - verified May 2010
Condition: Complications
Interventions: Device: Micropuncture needle set; Device: Standard gauge-18 needle set
Sponsor: Cook
Recruiting - verified August 2010
Condition: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsor: CSL Behring
Recruiting - verified August 2010
Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Vasomotor Symptoms; Menopause
Intervention: Drug: Mesafem Capsules
Sponsor: Noven Pharmaceuticals
Recruiting - verified August 2010
Condition: Osteopenia
Interventions: Drug: Placebo; Drug: AMG 167
Sponsor: Amgen
Recruiting - verified August 2010
Conditions: Acute Coronary Syndrome; Gout
Interventions: Drug: Febuxostat; Drug: Allopurinol
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Condition: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Drug: Asimadoline; Drug: Placebo
Sponsors: Tioga Pharmaceuticals; RTI Health Solutions
Recruiting - verified August 2010
Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
Interventions: Drug: Vancomycin; Drug: Vancomycin; Drug: Daptomycin 7-14 days moderate renal impairment; Drug: Daptomycin 7 - 14 days severe renal impairment, hemodialysis; Drug: Daptomycin 7 - 14 days severe renal impairment no hemodialysis; Drug: Daptomycin 14 - 42 days, moderate renal impairment; Drug: Daptomycin 14 - 42 days, severe renal impairment on hemodialysis; Drug: Daptomycin 14 - 42 days severe renal impairment, no hemodialysis
Sponsor: Cubist Pharmaceuticals
Recruiting - verified August 2010
Condition: Obesity
Interventions: Dietary Supplement: Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass; Dietary Supplement: Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate; Dietary Supplement: Very high protein diet group based on 1.4 gram of protein per pound of subject's lean body mass: 35% protein and 35% carbohydrate.
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified August 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsor: Actelion
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Drug: CP-601,927; Other: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitaliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 300 mg; Drug: sitaliptin 100 mg; Drug: Placebo/ sitagliptin 100 mg; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: placebo; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: LY500307; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Diagnostic Imaging
Interventions: Drug: PET tracer (BAY94-9392); Drug: PET tracer (BAY94-9392)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Cataract
Interventions: Device: Tecnis ZCB00 IOL; Device: Toric Intraocular lens
Sponsor: Abbott Medical Optics
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Colorectal Cancer
Intervention: Drug: Capecitabine + Perifosine or Placebo
Sponsor: Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Hypertension
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 12.5mg HCTZ
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: HIV Infections
Interventions: Biological: rAd35 Env A; Biological: rAd5 Env A; Biological: rAd5 Env B
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified August 2010
Condition: Parkinson's Disease
Intervention: Drug: IPX066
Sponsor: IMPAX Laboratories, Inc.
Recruiting - verified August 2010
Conditions: Keratoconus; Ectasia; Degeneration
Intervention:
Sponsor: Innovative Medical
Recruiting - verified September 2010
Condition: Stimulant Dependence
Interventions: Behavioral: Mindfulness Based Relapse Prevention; Behavioral: Health Education
Sponsor: University of California, Los Angeles
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: BI 671800; Drug: BI 671800; Drug: BI 671800; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Raynaud's Disease; Peripheral Vascular Disease
Interventions: Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791; Drug: PF-00489791
Sponsor: Pfizer
Recruiting - verified September 2010
Conditions: Major Depressive Disorder; Dysthymia; Depression Not Otherwise Specified; Borderline Personality Disorder
Interventions: Drug: Lithium Carbonate; Drug: Placebo; Drug: Citalopram
Sponsor: Columbia Northwest Pharmaceuticals
Recruiting - verified August 2010
Condition: Epilepsy
Interventions: Drug: Eslicarbazepine acetate 1600 mg; Drug: Eslicarbazepine acetate 1200 mg
Sponsor: Sepracor, Inc.
Recruiting - verified August 2010
Condition: Leukemia
Intervention: Drug: Bendamustine
Sponsor: Cephalon
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Intervention: Drug: ADP receptor inhibitors
Sponsors: Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Spondolyarthropathies
Interventions: Biological: Certolizumab pegol; Biological: Certolizumab pegol; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Placebo; Drug: Glimepiride
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Arthritis, Psoriatic
Interventions: Biological: CZP 200mg Q2W; Biological: CZP 400mg Q4W; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: Risperidone; Drug: Placebo; Drug: LY2140023
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab
Sponsor: Calistoga Pharmaceuticals, Inc.
Recruiting - verified August 2010
Conditions: Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: Levofloxacin; Drug: ACHN-490 Injection; Drug: ACHN-490 Injection
Sponsor: Achaogen, Inc.
Recruiting - verified August 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: rituximab
Sponsors: Genentech; Abbott
Recruiting - verified August 2010
Condition: Colorectal Cancer
Interventions: Drug: BMS-908662; Drug: BMS-908662; Drug: Cetuximab
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2010
Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Conditions: Cardiomyopathy; Pregnancy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified August 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: Investigator´s choice of chemotherapy
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Device: autoinjector; Device: pre-filled syringe
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Meniere's Disease
Interventions: Drug: OTO-104 (steroid) 3 mg; Drug: Placebo; Drug: OTO-104 (steroid) 12 mg
Sponsor: Otonomy, Inc.
Recruiting - verified June 2010
Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsors: BiPar Sciences; Sanofi-Aventis
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 300 mg; Drug: Canagliflozin 300 mg; Drug: Placebo/sitagliptin 100 mg; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Lupus Nephritis
Interventions: Drug: laquinimod 0.5mg + standard of care; Drug: laquinimod 1mg + standard of care; Other: placebo + standard of care
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Condition: Chronic Low Back Pain
Interventions: Drug: Placebo; Drug: Hydrocodone bitartrate
Sponsor: Zogenix, Inc.
Recruiting - verified August 2010
Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsor: Shire Pharmaceutical Development
Not yet recruiting - verified August 2010
Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: BMS-708163; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Recruiting - verified August 2010
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified August 2010
Condition: Joint Damage
Interventions: Drug: Febuxostat; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Smoking Cessation; Depression
Interventions: Drug: varenicline; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; Teva Pharmaceuticals USA
Recruiting - verified August 2010
Conditions: Hyperuricosuria; Kidney Stones
Interventions: Drug: Febuxostat; Drug: Allopurinol; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A); Drug: Bendamustine infusion (Arm B)
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: eptifibatide; Drug: unfractionated heparin placebo; Drug: unfractionated heparin; Drug: otamixaban (XRP0673); Drug: eptifibatide placebo; Drug: otamixaban placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Malignant Paraganglioma
Interventions: Drug: temozolomide; Drug: vorinostat; Genetic: DNA methylation analysis; Genetic: western blotting; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified August 2010
Conditions: Alzheimer's Disease; Central Nervous System Diseases; Cognition
Interventions: Drug: EVP-6124; Drug: Placebo
Sponsors: EnVivo Pharmaceuticals, Inc.; INC Research Limited
Recruiting - verified August 2010
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified August 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified November 2009
Conditions: C. Trachomatis; Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Cefixime; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified September 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Recruiting - verified August 2010
Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsor: Argos Therapeutics
Recruiting - verified August 2010
Condition: Intra-abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified August 2010
Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Neoplasm
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Regorafenib (BAY73-4506)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA); Other: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified August 2010
Condition: Diabetes Mellitus
Intervention: Drug: VIAject U-100 Insulin
Sponsors: Stanford University; Biodel; Barbara Davis Center for Childhood Diabetes
Not yet recruiting - verified August 2010
Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Lesch-Nyhan Disease
Intervention: Drug: Ecopipam
Sponsor: Psyadon Pharma
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Tachycardia, Ventricular
Intervention: Device: S-ICD System
Sponsor: Cameron Health, Inc.
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Daiichi Sankyo Inc.
Recruiting - verified September 2010
Condition: Influenza
Intervention: Drug: Peramivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified January 2010
Condition: Cytomegalovirus
Interventions: Drug: AIC246; Drug: AIC246; Drug: AIC246; Other: Placebo
Sponsors: AiCuris GmbH & Co.KG; Quintiles
Recruiting - verified August 2010
Conditions: Chronic Optic Nerve Atrophy; Non-Arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses
Sponsor: Quark Pharmaceuticals
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency
Interventions: Drug: Canagliflozin 300 mg; Drug: Placebo; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Ankylosing Spondylitis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191(REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: ATN-103; Drug: ATN-103; Drug: ATN-103
Sponsor: Wyeth
Recruiting - verified August 2010
Conditions: Cystitis, Interstitial; Urologic Diseases; Urinary Bladder Diseases; Cystitis
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Cardiovascular Disease
Interventions: Drug: dalcetrapib; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 2; Spinocerebellar Ataxia Type 3; Spinocerebellar Ataxia Type 6
Intervention:
Sponsors: University of Florida; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
Conditions: Bladder Cancer; Skin Cancers; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Intervention:
Sponsors: Stanford University; National Institutes of Health (NIH); Providence Foundation
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550; Drug: Atorvastatin; Drug: CP-690,550; Drug: Atorvastatin Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Mania; Bipolar I Disorder
Interventions: Drug: Cariprazine low dose; Drug: Cariprazine high dose; Drug: Placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified August 2010
Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified August 2010
Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Hepatitis C, Chronic
Intervention: Drug: Telaprevir/standard treatment
Sponsors: Tibotec Pharmaceuticals, Ireland; Vertex Pharmaceuticals Incorporated
Recruiting - verified August 2010
Condition: HIV Infections
Interventions: Biological: HIV-1 DNA plasmid vaccine; Biological: HIV-1 recombinant Ad5 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
Sponsor: Reata Pharmaceuticals, Inc.
Recruiting - verified August 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsors: Teva Neuroscience, Inc.; H. Lundbeck A/S
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo; Drug: Standard of Care
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Infections
Intervention: Drug: Moxifloxacin (Avelox, BAY12-8039)
Sponsor: Bayer
Recruiting - verified August 2010
Conditions: HAART Non-Adherence; HIV; HIV Infections
Intervention: Behavioral: Cell Phone Intervention
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Asthma; Chronic Disease
Intervention: Behavioral: Chronic Disease Self-Management Online Workshop
Sponsors: Stanford University; Alberta Health Services; National Council on Aging
Recruiting - verified August 2010
Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsor: Bristol-Myers Squibb
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Conditions: Breast Cancer; Ductal Breast Carcinoma in Situ; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Other: educational intervention; Procedure: quality-of-life assessment; Other: Questionnaire Administration; Other: psychosocial support for caregiver; Procedure: assessment of therapy complications; Other: informational intervention
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Figitumumab; Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: Conatumumab
Sponsor: Foundation for the National Institutes of Health
Recruiting - verified August 2010
Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified August 2010
Conditions: Leukemia Lymphoblastic, Acute; Acute Myeloid Leukemia; Neoplasm Recurrent
Interventions: Drug: Clofarabine; Radiation: Total Body Irradiation; Other: Stem Cell Infusion; Drug: Cyclosporins; Drug: Mycophenolate mofetil
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Conditions: Sexual Dysfunctions, Psychological; Depression
Interventions: Drug: flibanserin 2; Drug: placebo; Drug: flibanserin 1
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified September 2010
Conditions: Transfusional Iron Overload; Beta-Thalassemia
Intervention: Drug: FBS0701
Sponsor: FerroKin BioSciences, Inc.
Recruiting - verified December 2009
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: STA-9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified September 2010
Condition: Ankle Sprain
Interventions: Drug: FS-67; Other: Placebo
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
Recruiting - verified August 2010
Condition: Chronic Low Back Pain
Interventions: Drug: EN3324; Drug: Placebo
Sponsor: Endo Pharmaceuticals
Recruiting - verified August 2010
Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Conditions: Failed Back Surgery Syndrome; Leg Pain; Back Pain; Spinal Cord Stimulation
Interventions: Device: Precision Spinal Cord Stimulation; Procedure: Back Surgery
Sponsor: Boston Scientific Corporation
Recruiting - verified August 2010
Condition: Influenza
Intervention: Drug: oseltamivir [Tamiflu]
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified August 2010
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Imatinib mesylate; Drug: Imatinib mesylate; Drug: Imatinib mesylate
Sponsors: Sarcoma Alliance for Research through Collaboration; Novartis Pharmaceuticals
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified August 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
Condition: Influenza
Interventions: Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir; Drug: Oseltamivir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib; Drug: etoposide
Sponsor: OSI Pharmaceuticals
Recruiting - verified June 2010
Condition: Breast Cancer
Intervention:
Sponsor: City of Hope Medical Center
Recruiting - verified August 2010
Condition: Infection
Interventions: Drug: Ibuprofen; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified August 2010
Condition: Melanoma
Interventions: Drug: nilotinib (AMN107); Drug: decarbazine (DTIC)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Stage III Melanoma, Stage IV Melanoma
Intervention: Biological: MKC1106-MT
Sponsor: Mannkind Corporation
Not yet recruiting - verified August 2010
Condition: Spondylolisthesis
Intervention:
Sponsor: NuVasive
Recruiting - verified August 2010
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine, Bosutinib
Sponsors: University of California, San Francisco; University of Utah
Recruiting - verified August 2010
Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab
Sponsors: Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified August 2010
Condition: Castleman's Disease
Interventions: Other: Placebo; Drug: CNTO 328
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Condition: Parkinson Disease
Intervention:
Sponsors: Department of Veterans Affairs; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
Condition: Perennial Allergic Rhinitis
Interventions: Drug: Azelastine hydrochloride nasal spray 0.15%; Drug: Azelastine hydrochloride nasal spray 0.10%; Drug: Placebo
Sponsor: Meda Pharmaceuticals
Recruiting - verified August 2010
Condition: Neoplasms
Intervention: Drug: BI 6727, IV infusion
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Hepatic Insufficiency
Intervention: Drug: BMS-650032
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Fibromyalgia
Interventions: Drug: placebo; Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Fibromyalgia
Intervention: Drug: pregabalin
Sponsor: Pfizer
Not yet recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified June 2010
Condition: Cervical Intraepithelial Neoplasia
Interventions: Drug: RO5217790; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
Condition: Acne Vulgaris
Interventions: Drug: Tazarotene Foam; Drug: Vehicle Foam
Sponsor: Stiefel, a GSK Company
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2010
Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: Placebo; Drug: RO4917523; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: anti-CCR2 monoclonal antibody MLN1202; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified August 2010
Condition: Alzheimer Disease
Intervention: Drug: Florbetaben (BAY94-9172)
Sponsor: Bayer
Recruiting - verified August 2010
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
Sponsor: Seattle Genetics, Inc.
Recruiting - verified August 2010
Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Endometrial Cancer; Endometrial Neoplasms
Intervention: Drug: XL147
Sponsor: Exelixis
Recruiting - verified August 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Melanoma
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified August 2010
Condition: HIV
Intervention: Other: Observation
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified July 2010
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Advanced Pancreatic Cancer
Intervention: Drug: Tarceva, Gemcitabine, Nab-Paclitaxel
Sponsors: OSI Pharmaceuticals; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified April 2010
Condition: Liver Cancer
Interventions: Biological: cixutumumab; Drug: sorafenib tosylate; Other: laboratory biomarker analysis
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Condition: Prostate Cancer
Intervention: Other: SPECT-CT imaging
Sponsor: University of California, San Francisco
Recruiting - verified November 2009
Condition: Schizophrenia
Interventions: Drug: Paliperidone PR; Drug: Aripiprazole
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsor: Salix Pharmaceuticals
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Advanced Solid Tumors
Interventions: Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241; Drug: CVX-241
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL; Drug: Vehicle
Sponsors: Hologic, Inc.; PRA International
Recruiting - verified August 2010
Condition: Painful Diabetic Neuropathy
Intervention: Genetic: VM202
Sponsor: ViroMed Co., Ltd.
Recruiting - verified August 2010
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: PEG-rIL-29; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsors: ZymoGenetics; Bristol-Myers Squibb
Recruiting - verified September 2010
Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified August 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Gout
Interventions: Drug: RDEA594; Drug: Placebo; Drug: Allopurinol
Sponsor: Ardea Biosciences, Inc.
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate); Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Sponsor: Raptor Pharmaceutical Corp.
Recruiting - verified August 2010
Condition: Lymphoma, B-Cell
Interventions: Drug: Pralatrexate Injection; Dietary Supplement: Vitamin B12; Dietary Supplement: Folic Acid
Sponsor: Allos Therapeutics
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified September 2010
Condition: Coronary Artery Disease
Interventions: Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin
Sponsors: Boston Scientific Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified September 2010
Condition: Essential Hypertension
Interventions: Drug: Azilsartan medoxomil and chlorthalidone; Drug: Olmesartan medoxomil and hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Parkinson's Disease; Essential Tremor; Dystonia
Intervention: Device: Activa RC
Sponsor: MedtronicNeuro
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Neutral Protamine Hagedorn (NPH) insulin
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Condition: Arrhythmia Prophylaxis
Interventions: Drug: Celivarone (SSR149744); Drug: amiodarone; Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Spinocerebellar Ataxia Type 3
Interventions: Drug: varenicline; Drug: placebo
Sponsors: University of South Florida; National Ataxia Foundation; Bob Allison Ataxia Research Center (BAARC); Pfizer
Recruiting - verified July 2010
Conditions: HIV Infections; H1N1 Influenza Virus
Intervention: Biological: Influenza A (H1N1) monovalent vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Restless Legs Syndrome
Interventions: Drug: pregabalin; Drug: placebo; Drug: pramipexole
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Coronary Artery Disease
Intervention:
Sponsors: Scripps Health; Bristol-Myers Squibb; Sanofi-Aventis; Accumetrics, Inc.
Recruiting - verified August 2010
Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified August 2010
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified September 2010
Condition: Partial Epilepsy
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsors: Bial - Portela C S.A.; Sepracor, Inc.
Recruiting - verified August 2010
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Tibiotalar Arthrodesis; Subtalar Arthrodesis; Calcaneocuboid Arthrodesis; Talonavicular Arthrodesis; Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular); Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)
Intervention: Biological: Trinity Evolution
Sponsor: Orthofix Inc.
Recruiting - verified August 2010
Conditions: Parkinsons Disease With Dementia; Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Intervention: Drug: Rivastigmine Patch 9.5 cm2
Sponsors: University of California, San Francisco; Novartis
Recruiting - verified September 2009
Conditions: Pain; Back Pain; Low Back Pain; Back Pain With Radiation
Interventions: Drug: Oxycodone IR; Drug: NUCYNTA
Sponsors: Ortho-McNeil Janssen Scientific Affairs, LLC; Grünenthal
Recruiting - verified August 2010
Condition: Idiopathic Parkinson's Disease
Interventions: Biological: CERE-120: Adeno-Associated Virus Delivery of Neurturin; Procedure: Sham Surgery
Sponsor: Ceregene
Recruiting - verified August 2010
Conditions: H1N1 Influenza; Swine Flu
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2009
Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Oxepa; Dietary Supplement: Jevity 1.5; Dietary Supplement: Jevity 1.0
Sponsors: Massachusetts General Hospital; Muscular Dystrophy Association
Recruiting - verified August 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin (fixed dose); Drug: ribavirin (weight-based dose)
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified August 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: Hedgehog antagonist GDC-0449; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Solid Tumor; Kidney Neoplasms; Advanced Renal Cell Carcinoma
Interventions: Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Haemophilia A
Interventions: Drug: recombinant factor VIII (N8); Drug: recombinant factor VIII (N8)
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Condition: Breast Cancer
Interventions: Drug: BIIB021; Drug: BIIB021; Drug: exemestane (Aromasin)
Sponsor: Biogen Idec
Recruiting - verified August 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified August 2010
Condition: C. Trachomatis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2010
Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Hemophilia B
Intervention: Genetic: Gene Transfer
Sponsors: St. Jude Children's Research Hospital; Stanford University; Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified August 2010
Condition: Multiple System Atrophy
Interventions: Drug: rasagiline mesylate; Other: placebo
Sponsors: Teva Pharmaceutical Industries; H. Lundbeck A/S
Recruiting - verified August 2010
Condition: Schizophrenia
Interventions: Drug: PF-03463275; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Sitagliptin
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Chemotherapy + figitumumab; Drug: Chemotherapy
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Hyperparathyroidism, Primary
Interventions: Drug: cinacalcet HCl; Drug: Placebo
Sponsor: Amgen
Recruiting - verified August 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified August 2010
Conditions: HIV Infections; Treatment Experienced
Interventions: Biological: DNA + HIV-rAd5 vaccine; Drug: ART intensification (raltegravir); Drug: ART intensification (maraviroc)
Sponsors: Northwestern University; ORVACS (Objectif Recherche Vaccin SIDA); National Institute of Allergy and Infectious Diseases (NIAID); Pfizer; Merck
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Acute On Chronic Hepatitis
Interventions: Device: Extracorporeal Liver Assist Device (ELAD); Other: Standard of care
Sponsor: Vital Therapies, Inc.
Recruiting - verified May 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: JNJ-28431754; Drug: glimepiride
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
Conditions: Schizophrenia; Central Nervous System Diseases; Cognition
Interventions: Drug: EVP-6124; Drug: Placebo
Sponsors: EnVivo Pharmaceuticals, Inc.; INC Research Limited
Recruiting - verified August 2010
Condition: Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery using the Novalis Tx
Sponsor: San Diego Radiosurgery
Recruiting - verified August 2010
Conditions: Colorectal Cancer; Neoplasms, Colorectal
Interventions: Drug: CS7017; Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified August 2010
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Erlotinib; Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsor: Celgene Corporation
Recruiting - verified August 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Hypercholesterolemia
Intervention: Dietary Supplement: LIP-01
Sponsor: Afexa Life Sciences Inc
Recruiting - verified August 2010
Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified September 2010
Conditions: Spinal Cord Stimulation; Deep Brain Stimulation; Drug Infusion (Implantable Pumps); Sacral Nerve Stimulation
Intervention: Device: Various
Sponsor: MedtronicNeuro
Recruiting - verified August 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine and Fluoxetine combination; Drug: Fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Conditions: Cough; Sore Throat; Nasal Congestion; Headache; Fever; Seasonal Influenza
Interventions: Drug: Peramivir 600mg Adults, Peramivir 10mg/kg Adolescents; Drug: Placebo Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified July 2010
Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Depression
Intervention: Device: Transcranial Magnetic Stimulation
Sponsor: University of California, Los Angeles
Recruiting - verified July 2010
Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Hematologic Malignancies
Interventions: Drug: PF-04449913; Drug: dasatinib
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: AMG 827 70 mg; Drug: AMG 827 140 mg; Drug: AMG 827 210 mg
Sponsor: Amgen
Recruiting - verified September 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified August 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Diabetes Mellitus
Intervention: Drug: Generex Oral-lyn™
Sponsor: Generex Biotechnology Corp.
Available - verified August 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified May 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Condition: Factor XIII Deficiency
Intervention: Biological: FXIII Concentrate Human
Sponsor: CSL Behring
Recruiting - verified August 2010
Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Cancer
Intervention: Drug: dalteparin
Sponsor: Eisai Inc.
Recruiting - verified August 2010
Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified September 2010
Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Adenoma; Prolactinoma
Intervention: Drug: Lapatinib
Sponsor: Cedars-Sinai Medical Center
Recruiting - verified September 2010
Condition: Relapsed Acute Myelogenous Leukemia
Interventions: Drug: clofarabine; Drug: etoposide; Drug: cyclophosphamide; Drug: filgrastim; Drug: cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified August 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Condition: Melanoma (Skin)
Intervention: Drug: dinaciclib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified August 2010
Conditions: Neoplasms; Melanoma; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: PF-04217329; Drug: PF-04217329 + latanoprost
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Prostate Cancer
Intervention: Behavioral: Atkins Diet
Sponsors: Duke University; VA Greater Los Angeles Healthcare System; Durham VA Medical Center; University of California, Los Angeles; Santa Monica UCLA Medical Center
Recruiting - verified August 2010
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Advanced Solid Tumors
Intervention: Drug: PF-03758309
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Conditions: West Nile Neuroinvasive Disease; West Nile Virus Infection; Encephalitis; Meningitis; Acute Flaccid Paralysis; West Nile Fever
Interventions: Biological: MGAWN1; Biological: Placebo - normal saline
Sponsors: MacroGenics; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2010
Condition: Cancer
Intervention: Drug: PF-04691502
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Major Depressive Disorder
Interventions: Device: Brainsway H-Coil Deep TMS System; Device: Brainsway H-Coil Deep TMS System (Sham treatment)
Sponsor: Brainsway
Recruiting - verified August 2010
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified August 2010
Condition: Bone Mineral Density
Interventions: Drug: DR-105; Drug: Lessina®; Other: Control Group
Sponsor: Duramed Research
Recruiting - verified August 2010
Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified July 2010
Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified September 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: bone scan; Procedure: scintigraphy; Radiation: calcium-41 chloride aqueous solution; Radiation: calcium-46 chloride aqueous solution
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: NX-1207; Drug: Placebo
Sponsor: Nymox Corporation
Recruiting - verified August 2010
Conditions: Gastric Cancer; Adenocarcinoma
Interventions: Biological: ramucirumab; Other: Placebo; Other: Best Supportive Care
Sponsor: ImClone LLC
Recruiting - verified August 2010
Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsor: NovoCure Ltd.
Recruiting - verified August 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified August 2010
Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Procedure: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010
Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified August 2010
Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified April 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified May 2010
Condition: Parkinson Disease
Interventions: Drug: isradipine cr; Drug: placebo/ sugar pill
Sponsors: The Parkinson Study Group; Michael J. Fox Foundation for Parkinson's Research; Northwestern University Dixon Fund
Recruiting - verified August 2010
Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2010
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified September 2010
Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention:
Sponsor: Scripps Health
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified August 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsor: Bayer
Recruiting - verified August 2010
Conditions: Venous Leg Ulcer; Venous Stasis Ulcer
Intervention:
Sponsor: Healthpoint
Recruiting - verified August 2010
Conditions: Alzheimer's Disease; Agitation
Interventions: Drug: citalopram; Drug: placebo
Sponsors: Johns Hopkins University; National Institute on Aging (NIA); National Institute of Mental Health (NIMH)
Recruiting - verified September 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: HIV Infections; Acquired Immunodeficiency Syndrome
Interventions: Drug: ATV/rtv 300/100mg; Drug: 48 weeks ATV/rtv 300/100mg once daily + ETR 200mg twice daily; Drug: ATV/rtv 400/100mg; Drug: TDF 300mg
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified August 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Conditions: Depression; Mood Disorders; Depressive Disorder
Intervention: Drug: Citalopram
Sponsor: Stanford University
Recruiting - verified August 2010
Conditions: Acute Ischemic Stroke; Stroke; Brain Infarction
Interventions: Drug: Eptifibatide; Drug: rt-PA
Sponsors: University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2010
Condition: Locally Advanced or Metastatic Pancreatic Cancer
Intervention: Drug: FG-3019
Sponsor: FibroGen
Recruiting - verified August 2010
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified June 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Crohn's Disease
Interventions: Drug: certolizumab pegol; Drug: certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified September 2010
Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsor: Wyeth
Recruiting - verified August 2010
Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Leukemia; Leukemia Acute Myeloid Leukemia (AML)
Interventions: Drug: lenalidomide; Drug: Azacitidine
Sponsors: Stanford University; Celgene Corporation
Recruiting - verified August 2010
Condition: Non-Cystic Fibrosis Bronchiectasis
Interventions: Drug: Ciprofloxacin for Inhalation; Drug: Ciprofloxacin for Inhalation; Drug: Placebo
Sponsor: Aradigm Corporation
Recruiting - verified August 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified August 2010
Condition: Lung Cancer
Interventions: Biological: cixutumumab; Drug: Hedgehog antagonist GDC-0449; Drug: cisplatin; Drug: etoposide phosphate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Conditions: Cryptococcal Meningitis; HIV Infections
Interventions: Drug: Fluconazole; Drug: Amphotericin B
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2010
Condition: Alzheimer Disease
Interventions: Drug: RO5313534; Drug: RO5313534; Drug: RO5313534; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: LY2127399; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010